Natalia Rompoti

16PUBLICATIONS

40CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMajor global burdens of diseasePredictive and prognostic markersAutoimmunity

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (16)

Sort by Publication Date:

|Jun 16, 2026

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

|Jun 05, 2025

Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study.

Ioannis-Alexios Koumprentziotis, Irene Stefanaki, Natalia Rompoti

|Mar 29, 2025

Systemic inflammation correlates with depression and lower quality of life in patients with hidradenitis suppurativa independent of disease severity.

Nikolaos Rotsiamis, Natalia Rompoti, Aikaterini Liakou

|Feb 22, 2025

Risk of second primary cancers in patients with Merkel cell carcinoma: A systematic review and meta-analysis.

Ioannis-Alexios Koumprentziotis, Aikaterini Tsiogka, Natalia Rompoti

|Jan 17, 2025

Bimekizumab Treatment for Scalp Psoriasis: A 52-Week, Real-World, Retrospective Study.

Irene Stefanaki, Ioannis-Alexios Koumprentziotis, Natalia Rompoti

|Dec 31, 2024

Single-center experience with bimekizumab in psoriasis patients with previous exposure to interleukin-17 inhibitors.

Ioannis-Alexios Koumprentziotis, Natalia Rompoti, Irene Stefanaki

Pageof 3

Frequent Collaborators

6 joint publications

Electra Nicolaidou

5 joint publications

Ioannis-Alexios Koumprentziotis

Evangelia Papadavid

Irene Stefanaki

Stamatis Gregoriou

P Sidiropoulou

Aikaterini Tsiogka

Alexander Katoulis

Andreas G Tsantes

Aikaterini Liakou

Frequent Collaborators

6 joint publications

Electra Nicolaidou

5 joint publications

Ioannis-Alexios Koumprentziotis

4 joint publications

Evangelia Papadavid

4 joint publications

Irene Stefanaki